Huge demand for weight-loss treatments offers rich rewards but the leading pharma groups will not cede ground easily
Obesity drug challengers will struggle to break into plus-sized market
Recent Posts
- Danone to buy meal-in-bottle maker Huel in €1bn deal
- Flights disrupted after crash at NY’s LaGuardia airport kills two people
- Gilt rout deepens as traders bet on four BoE rate rises this year
- Qatar Airways parks long-haul jets in storage in Spain
- London police chief warns of ‘sustained threat’ from Iranian state plots
